Literature DB >> 20832876

Imbalance between pro-angiogenic and anti-angiogenic factors in rheumatic and mixomatous mitral valves.

Giovanni Mariscalco1, Roberto Lorusso, Fausto Sessa, Vito Domenico Bruno, Gabriele Piffaretti, Maciej Banach, Paolo Cattaneo, Giuseppe Paolo Cozzi, Andrea Sala.   

Abstract

BACKGROUND: A balance between angiogenic and anti-angiogenic factors is critical in tissue development, tissue repair and homeostasis. Aberrant angiogenesis has been implicated in several pathologic conditions, including valvular heart disease. The aim of this study was to ascertain the pathogenetic role of angiogenesis in rheumatic and mixomatous mitral valve diseases.
METHODS: Leaflets from mixomatous (n=20) and rheumatic (n=20) mitral valves removed from surgical patients, and normal mitral valve (n=6) obtained at autopsy were collected. Immunohistochemical studies were performed on sequential valve sections, evaluating CD31, CD34, α smooth muscle actin (α-SMA), vascular endothelial growth factor (VEGF), VEGF receptor-1 (VEGFR1), VEGF receptor-2 (VEGFR-2), and chondromodulin-I (Chm-I).
RESULTS: Immunohistochemistry revealed significant differences among groups in CD31 (p=0.001), CD34 (p<0.001), α-SMA (p<0.001), VEGF (p<0.001), VEGFR1 (p=0.007), VEGFR2 (p=0.011), and Chm-I (p<0.001) expressions. Rheumatic valves demonstrated a severe up-regulation and down-regulation in pro-angiogenic and anti-angiogenic factors, respectively, compared with mixomatous and normal mitral valves. On the contrary, mixomatous valves showed a significant up-regulation of anti-angiogenic factors with respect to rheumatic and normal valves.
CONCLUSIONS: These findings provide evidence that an imbalance between pro-angiogenic and anti-angiogenic factors is implicated in mitral valve disease. Pro-angiogenic factors are up-regulated in rheumatic disease, while anti-angiogenic ones in mixomatous mitral valves.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20832876     DOI: 10.1016/j.ijcard.2010.08.001

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Aneurysm Development in Patients With Bicuspid Aortic Valve (BAV): Possible Connection to Repair Deficiency?

Authors:  Shohreh Maleki; Hanna M Björck; Valentina Paloschi; Sanela Kjellqvist; Lasse Folkersen; Veronica Jackson; Anders Franco-Cereceda; Per Eriksson
Journal:  Aorta (Stamford)       Date:  2013-06-01

Review 2.  Cellular mechanisms in mitral valve disease.

Authors:  Kareem Salhiyyah; Magdi H Yacoub; Adrian H Chester
Journal:  J Cardiovasc Transl Res       Date:  2011-09-03       Impact factor: 4.132

3.  Differential cell-matrix responses in hypoxia-stimulated aortic versus mitral valves.

Authors:  Matthew C Sapp; Varun K Krishnamurthy; Daniel S Puperi; Saheba Bhatnagar; Gabrielle Fatora; Neelesh Mutyala; K Jane Grande-Allen
Journal:  J R Soc Interface       Date:  2016-12       Impact factor: 4.118

4.  Regulation of valve endothelial cell vasculogenic network architectures with ROCK and Rac inhibitors.

Authors:  C Alexander Arevalos; Amanda T Walborn; Amanda A Rupert; Jonathan M Berg; Elizabeth L Godfrey; Jacqueline M V Nguyen; K Jane Grande-Allen
Journal:  Microvasc Res       Date:  2015-02-03       Impact factor: 3.514

5.  Analysis of immunostaining and western blotting of endothelin 1 and its receptors in mitral stenosis.

Authors:  Sydney Correia Leão; Michael R Dashwood; Mateus Santana de Andrade; Nicolas Nascimento Santos; Olivia Regina Lins Leal Teles; Williasmin Batista de Souza; Tania Maria de Andrade Rodrigues
Journal:  Rev Bras Cir Cardiovasc       Date:  2015 Mar-Apr

6.  Association between inflammatory biomarkers and thin-cap fibroatheroma detected by optical coherence tomography in patients with coronary heart disease.

Authors:  Kohei Koyama; Kihei Yoneyama; Takanobu Mitarai; Yuki Ishibashi; Eiji Takahashi; Ken Kongoji; Tomoo Harada; Yoshihiro J Akashi
Journal:  Arch Med Sci       Date:  2015-06-19       Impact factor: 3.318

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.